WO2001032127A2 - Procede et compositions pour traiter des maladies respiratoires - Google Patents

Procede et compositions pour traiter des maladies respiratoires Download PDF

Info

Publication number
WO2001032127A2
WO2001032127A2 PCT/US2000/030113 US0030113W WO0132127A2 WO 2001032127 A2 WO2001032127 A2 WO 2001032127A2 US 0030113 W US0030113 W US 0030113W WO 0132127 A2 WO0132127 A2 WO 0132127A2
Authority
WO
WIPO (PCT)
Prior art keywords
pde
compounds
pde4
rolipram
asthma
Prior art date
Application number
PCT/US2000/030113
Other languages
English (en)
Other versions
WO2001032127A3 (fr
Inventor
Peter N. Goodfellow
Richard Nieman
Theodore J. Torphy
Original Assignee
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to KR1020027005609A priority Critical patent/KR20020057988A/ko
Priority to AU13575/01A priority patent/AU1357501A/en
Application filed by Smithkline Beecham Corporation filed Critical Smithkline Beecham Corporation
Priority to APAP/P/2002/002496A priority patent/AP2002002496A0/en
Priority to EA200200518A priority patent/EA200200518A1/ru
Priority to PL00355261A priority patent/PL355261A1/xx
Priority to DZ003225A priority patent/DZ3225A1/fr
Priority to HU0203152A priority patent/HUP0203152A3/hu
Priority to CA002388333A priority patent/CA2388333A1/fr
Priority to BR0015270-6A priority patent/BR0015270A/pt
Priority to SK759-2002A priority patent/SK7592002A3/sk
Priority to IL14936700A priority patent/IL149367A0/xx
Priority to JP2001534335A priority patent/JP2003513028A/ja
Priority to MXPA02004350A priority patent/MXPA02004350A/es
Priority to EP00975533A priority patent/EP1225866A4/fr
Publication of WO2001032127A2 publication Critical patent/WO2001032127A2/fr
Publication of WO2001032127A3 publication Critical patent/WO2001032127A3/fr
Priority to NO20022057A priority patent/NO20022057L/no
Priority to BG106748A priority patent/BG106748A/xx
Priority to HK02109234.5A priority patent/HK1049107A1/zh
Priority to US11/217,532 priority patent/US20060035877A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne le traitement de maladies respiratoires telles que la maladie respiratoire obstructive chronique ou l'asthme par l'administration d'un inhibiteur de phosphodiestérase 4 en combinaison avec un corticostéroïde anti-inflammatoire.
PCT/US2000/030113 1999-11-02 2000-11-01 Procede et compositions pour traiter des maladies respiratoires WO2001032127A2 (fr)

Priority Applications (18)

Application Number Priority Date Filing Date Title
IL14936700A IL149367A0 (en) 1999-11-02 2000-11-01 Method and compositions for treating pulmonary diseases
SK759-2002A SK7592002A3 (en) 1999-11-02 2000-11-01 Method and compositions for treating pulmonary diseases
JP2001534335A JP2003513028A (ja) 1999-11-02 2000-11-01 肺疾患を治療するための方法および組成物
AU13575/01A AU1357501A (en) 1999-11-02 2000-11-01 Method and compositions for treating pulmonary diseases
PL00355261A PL355261A1 (en) 1999-11-02 2000-11-01 Method and compositions for treating pulmonary diseases
DZ003225A DZ3225A1 (fr) 1999-11-02 2000-11-01 Methode et compositions pour le traitement des maladies pulmonaires
HU0203152A HUP0203152A3 (en) 1999-11-02 2000-11-01 Method and compositions for treating pulmonary diseases
CA002388333A CA2388333A1 (fr) 1999-11-02 2000-11-01 Procede et compositions pour traiter des maladies respiratoires
BR0015270-6A BR0015270A (pt) 1999-11-02 2000-11-01 Método e composições para tratamento de doenças pulmonares
KR1020027005609A KR20020057988A (ko) 1999-11-02 2000-11-01 폐 질환을 치료하는 방법 및 조성물
EA200200518A EA200200518A1 (ru) 1999-11-02 2000-11-01 Способ и композиция для лечения заболеваний легких
APAP/P/2002/002496A AP2002002496A0 (en) 1999-11-02 2000-11-01 Method and compositions for treating pulmonary diseases.
MXPA02004350A MXPA02004350A (es) 1999-11-02 2000-11-01 Metodo y composiciones para tratar enfermedades pulmonares.
EP00975533A EP1225866A4 (fr) 1999-11-02 2000-11-01 Procede et compositions pour traiter des maladies respiratoires
NO20022057A NO20022057L (no) 1999-11-02 2002-04-30 Fremgangsmåte og sammensetning for å behandle lungesykdommer
BG106748A BG106748A (en) 1999-11-02 2002-05-29 Method and compositions for treating pulmonary diseases
HK02109234.5A HK1049107A1 (zh) 1999-11-02 2002-12-19 用於治療肺疾病的方法和組合物
US11/217,532 US20060035877A1 (en) 1999-11-02 2005-09-01 Method and compositions for treating pulmonary diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16315899P 1999-11-02 1999-11-02
US60/163,158 1999-11-02

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10129311 A-371-Of-International 2002-05-02
US10/847,223 Continuation US20040214805A1 (en) 1999-11-02 2004-05-17 Method and compositions for treating pulmonary diseases

Publications (2)

Publication Number Publication Date
WO2001032127A2 true WO2001032127A2 (fr) 2001-05-10
WO2001032127A3 WO2001032127A3 (fr) 2001-12-06

Family

ID=22588737

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/030113 WO2001032127A2 (fr) 1999-11-02 2000-11-01 Procede et compositions pour traiter des maladies respiratoires

Country Status (29)

Country Link
EP (1) EP1225866A4 (fr)
JP (1) JP2003513028A (fr)
KR (1) KR20020057988A (fr)
CN (1) CN1387404A (fr)
AP (1) AP2002002496A0 (fr)
AR (1) AR029189A1 (fr)
AU (1) AU1357501A (fr)
BG (1) BG106748A (fr)
BR (1) BR0015270A (fr)
CA (1) CA2388333A1 (fr)
CO (1) CO5261512A1 (fr)
CZ (1) CZ20021512A3 (fr)
DZ (1) DZ3225A1 (fr)
EA (1) EA200200518A1 (fr)
EC (1) ECSP003747A (fr)
HK (1) HK1049107A1 (fr)
HU (1) HUP0203152A3 (fr)
IL (1) IL149367A0 (fr)
MA (1) MA26841A1 (fr)
MX (1) MXPA02004350A (fr)
NO (1) NO20022057L (fr)
OA (1) OA12076A (fr)
PE (1) PE20011005A1 (fr)
PL (1) PL355261A1 (fr)
SK (1) SK7592002A3 (fr)
TR (1) TR200201211T2 (fr)
TW (1) TWI242431B (fr)
WO (1) WO2001032127A2 (fr)
ZA (1) ZA200203435B (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003024489A2 (fr) * 2001-09-19 2003-03-27 Altana Pharma Ag Combinaison d'un ains et d'un inhibiteur de pde4
WO2003037349A1 (fr) * 2001-10-31 2003-05-08 Merck Patent Gmbh Inhibiteurs de la phosphodiesterase de type 4 et leurs utilisations
WO2004035038A1 (fr) * 2002-10-17 2004-04-29 Ono Pharmaceutical Co., Ltd. Agent therapeutique contre la broncho-pneumopathie chronique obstructive
WO2004087149A1 (fr) * 2003-03-31 2004-10-14 Kyowa Hakko Kogyo Co. Ltd. Composition therapeutique
JP2005539042A (ja) * 2002-08-09 2005-12-22 ヴィアトリス ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディートゲゼルシャフト 呼吸器疾患、アレルギー性疾患、喘息及びｃｏｐｄを処置するためのグルココルチコイド及びｐｄｅ−４−阻害剤の新規組合せ
EP1651167A2 (fr) * 2003-07-31 2006-05-03 Epigenesis Pharmaceuticals LLC Combinaison de dehydroepiandrosterone ou de sulfate de dehydroepiandrosterone et d'un inhibiteur de pde-4 pour le traitement de l'asthme ou d'une maladie obstructive respiratoire
WO2007045980A1 (fr) * 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Compositions d'inhibiteurs de la phosphodiesterase de type iv
WO2015063669A1 (fr) 2013-10-30 2015-05-07 Wockhardt Limited Compositions pharmaceutiques comprenant une combinaison de roflumilast et d'acébrophylline ou de leurs sels pharmaceutiquement acceptables
US9974909B2 (en) 2010-01-05 2018-05-22 Microdose Therapeutx, Inc. Inhalation device and method

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2006041121A1 (ja) * 2004-10-13 2008-05-15 協和醗酵工業株式会社 慢性皮膚疾患の治療および／または予防剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1466598A3 (fr) * 1993-06-18 2007-06-27 Smithkline Beecham Corporation Inhibiteurs de pde 4
DE4332041C2 (de) * 1993-09-21 1997-12-11 Rentschler Arzneimittel Verwendung von Pentoxifyllin bei bestimmten Lungenerkrankungen
PE44995A1 (es) * 1994-01-27 1995-12-18 Schering Corp Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias
SE9801368D0 (sv) * 1998-04-20 1998-04-20 Astra Ab New use

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE BIOSIS [Online] DEPT. PHARMACOL., KING'S COLL. LONDON, (LONDON, UK) BANNER ET AL.: 'The effect of selective phosphodiesterase inhibitors in comparison with other anti-asthma drugs on allergen-induced eosinophilia in Guinea-Pig airways', XP002938256 Retrieved from STN Database accession no. 1995:554394 & PULMONERY PHARMACOLOGY vol. 8, no. 1, 1995, pages 37 - 42 *
DATABASE CA [Online] DEPARTMENT OF PHARMACOLOGY, GIFU PHARMACEUTICAL UNIVERSITY, (GIFU, JAPAN) KIMATA ET AL.: 'Pharmacological modulation of LPS-induced MIP-1 or production by peripheral blood mononuclear cells', XP002938253 Retrieved from STN Database accession no. 128:265772 & PHARMACOLOGY vol. 56, no. 5, 1998, pages 230 - 236 *
DATABASE CA [Online] DEPARTMENT OF PHARMACOLOGY, KING'S COLLEGE LONDON, (LONDON, ENGLAND) BANNER ET AL.: 'The effect of selective phosphodiesterase 3 and 4 isoenzyme inhibitors and established anti-asthma drugs on inflammatory cell activation', XP002938254 Retrieved from STN Database accession no. 126:14486 & BR. J. PHARMACOL. vol. 119, no. 6, 1996, pages 1255 - 1261 *
DATABASE CA [Online] INFLAMMATION BIOLOGY, THERAPEUTICS, LTD. (SLOUGH, UK) GOZZARD ET AL.: 'Effect of the glucocorticosteroid budesonide and a novel phosphodiesterase Type 4 inhibitor CDP840 on antigen-induced airway responses in neonatally immunized rabbits', XP002938255 Retrieved from STN Database accession no. 125:132083 & BR. J. PHARMACOL. vol. 118, no. 5, 1996, pages 1201 - 1208 *
See also references of EP1225866A2 *

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA008108B1 (ru) * 2001-09-19 2007-04-27 Алтана Фарма Аг Комбинация нспвлс и ингибитора pde-4
WO2003024489A3 (fr) * 2001-09-19 2003-09-18 Altana Pharma Ag Combinaison d'un ains et d'un inhibiteur de pde4
WO2003024489A2 (fr) * 2001-09-19 2003-03-27 Altana Pharma Ag Combinaison d'un ains et d'un inhibiteur de pde4
US8242146B2 (en) 2001-09-19 2012-08-14 Nycomed Gmbh Combination of a NSAID and a PDE-4 inhibitor
WO2003037349A1 (fr) * 2001-10-31 2003-05-08 Merck Patent Gmbh Inhibiteurs de la phosphodiesterase de type 4 et leurs utilisations
JP2005539042A (ja) * 2002-08-09 2005-12-22 ヴィアトリス ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディートゲゼルシャフト 呼吸器疾患、アレルギー性疾患、喘息及びｃｏｐｄを処置するためのグルココルチコイド及びｐｄｅ−４−阻害剤の新規組合せ
WO2004035038A1 (fr) * 2002-10-17 2004-04-29 Ono Pharmaceutical Co., Ltd. Agent therapeutique contre la broncho-pneumopathie chronique obstructive
WO2004087149A1 (fr) * 2003-03-31 2004-10-14 Kyowa Hakko Kogyo Co. Ltd. Composition therapeutique
EP1651167A2 (fr) * 2003-07-31 2006-05-03 Epigenesis Pharmaceuticals LLC Combinaison de dehydroepiandrosterone ou de sulfate de dehydroepiandrosterone et d'un inhibiteur de pde-4 pour le traitement de l'asthme ou d'une maladie obstructive respiratoire
EP1651167A4 (fr) * 2003-07-31 2009-04-01 Epigenesis Pharmaceuticals Llc Combinaison de dehydroepiandrosterone ou de sulfate de dehydroepiandrosterone et d'un inhibiteur de pde-4 pour le traitement de l'asthme ou d'une maladie obstructive respiratoire
WO2007045980A1 (fr) * 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Compositions d'inhibiteurs de la phosphodiesterase de type iv
US9974909B2 (en) 2010-01-05 2018-05-22 Microdose Therapeutx, Inc. Inhalation device and method
US10434267B2 (en) 2010-01-05 2019-10-08 Microdose Therapeutx, Inc. Inhalation device and method
WO2015063669A1 (fr) 2013-10-30 2015-05-07 Wockhardt Limited Compositions pharmaceutiques comprenant une combinaison de roflumilast et d'acébrophylline ou de leurs sels pharmaceutiquement acceptables

Also Published As

Publication number Publication date
NO20022057L (no) 2002-06-27
OA12076A (en) 2006-05-04
NO20022057D0 (no) 2002-04-30
PL355261A1 (en) 2004-04-05
CZ20021512A3 (cs) 2003-04-16
ZA200203435B (en) 2003-06-25
IL149367A0 (en) 2002-11-10
BG106748A (en) 2003-02-28
PE20011005A1 (es) 2001-09-28
ECSP003747A (es) 2002-05-23
SK7592002A3 (en) 2002-11-06
EP1225866A2 (fr) 2002-07-31
AU1357501A (en) 2001-05-14
CO5261512A1 (es) 2003-03-31
CA2388333A1 (fr) 2001-05-10
HUP0203152A2 (hu) 2003-01-28
HUP0203152A3 (en) 2004-06-28
CN1387404A (zh) 2002-12-25
MXPA02004350A (es) 2002-11-07
KR20020057988A (ko) 2002-07-12
BR0015270A (pt) 2002-06-18
JP2003513028A (ja) 2003-04-08
TWI242431B (en) 2005-11-01
EP1225866A4 (fr) 2004-04-21
AR029189A1 (es) 2003-06-18
EA200200518A1 (ru) 2002-10-31
AP2002002496A0 (en) 2002-06-30
HK1049107A1 (zh) 2003-05-02
WO2001032127A3 (fr) 2001-12-06
DZ3225A1 (fr) 2001-05-10
MA26841A1 (fr) 2004-12-20
TR200201211T2 (tr) 2002-08-21

Similar Documents

Publication Publication Date Title
US20050070514A1 (en) Therapies for treating respiratory diseases
US6555583B2 (en) Therapies for treating pulmonary diseases
Skoner Balancing safety and efficacy in pediatric asthma management
CZ219196A3 (en) Application of mometasonfuorate aqueous suspension for preparing a medicament for effective intranasal treatment of nasal allergy
SA04250122B1 (ar) دواء جديد يحتوي على العامل المساعد بيتا 2 شديد الفعالية وطويل المفعول وذلك بالاتحاد مع مكونات فعاله أخرى
US20060069155A1 (en) Method for reducing exacerbations associated with COPD
EP1411914A2 (fr) UTILISATION D'UN INHIBITEUR DE LA pde4 EN ASSOCIATION AVEC UN AGENT ANTICHOLINERGIQUE POUR LE TRAITEMENT D'UNE MALADIE PULMONAIRE, PAR EXAMPLE L'ASTHME
US20040176419A1 (en) Composition comprising a pde-4 inhibitor and h1-receptor antagonist and the use thereof for the manufacture of a medicament for the treatment of respiratory diseases
EP1225866A2 (fr) Procede et compositions pour traiter des maladies respiratoires
US20140329782A1 (en) Combined therapeutic agent
WO2004019984A1 (fr) Nouvelle combinaison de glucocorticoides et d'inhibiteurs de pde-4 pour traiter des maladies des voies respiratoires, des maladies allergiques, de l'asthme et des maladies pulmonaires chroniques obstructives
AU2001279023B2 (en) Method for reducing exacerbations associated with COPD
US20060035877A1 (en) Method and compositions for treating pulmonary diseases
Meltzer Pharmacological treatment options for allergic rhinitis and asthma.
Berger Budesonide inhalation suspension for the treatment of asthma in infants and children
AU2004205324A1 (en) Method and compositions for treating pulmonary diseases
EP1261331A1 (fr) Procede et compositions permettant de traiter les maladies fibrosantes
US20030018071A1 (en) Method and compositions for treating fibrotic diseases
KR20050094810A (ko) 로플루미래스트와 ｒ,ｒ-포르모테롤을 포함하는 상승작용성조합물
AU2002310620A1 (en) Composition comprising a PDE-4 inhibitor and H1-receptor antagonist and the use thereof for the manufacture of a medicament for the treatment respiratory diseases
CN107737105A (zh) 一种鼻腔用盐酸氮卓斯汀组合物喷雾剂及生产工艺
Update Drug Class Review Controller Medications for Asthma
AU2002321261A1 (en) Use of a PDE4 inhibitor in combination with an anticholinergic agent for the treatment of pulmonary disease such as asthma

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AU BA BB BG BR BZ CA CN CZ DZ EE GE GH GM HR HU ID IL IN IS JP KP KR LC LK LR LT LV MA MG MK MN MX MZ NO NZ PL RO SG SI SK SL TR TT TZ UA US UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AU BA BB BG BR BZ CA CN CZ DZ EE GE GH GM HR HU ID IL IN IS JP KP KR LC LK LR LT LV MA MG MK MN MX MZ NO NZ PL RO SG SI SK SL TR TT TZ UA US UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 13575/01

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1200200361

Country of ref document: VN

WWE Wipo information: entry into national phase

Ref document number: 518564

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 149367

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: PV2002-1512

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/004350

Country of ref document: MX

Ref document number: 008152659

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 2001 534335

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020027005609

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2388333

Country of ref document: CA

Ref document number: 10129311

Country of ref document: US

Ref document number: 2002/01211

Country of ref document: TR

WWE Wipo information: entry into national phase

Ref document number: 2000975533

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: DZP2002000114

Country of ref document: DZ

ENP Entry into the national phase

Ref document number: 2000 106748

Country of ref document: BG

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 7592002

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: 200200518

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 1020027005609

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2000975533

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV2002-1512

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 2000975533

Country of ref document: EP

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)